ValuEngine cut shares of Microbot Medical (NASDAQ:MBOT) from a buy rating to a hold rating in a report published on Tuesday morning, ValuEngine reports.

Separately, HC Wainwright reaffirmed a buy rating and set a $10.00 price objective on shares of Microbot Medical in a report on Wednesday, August 21st.

NASDAQ:MBOT traded down $0.04 during trading hours on Tuesday, hitting $6.26. The stock had a trading volume of 13,628 shares, compared to its average volume of 199,295. The company has a 50 day simple moving average of $5.99 and a two-hundred day simple moving average of $6.56. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.69 and a quick ratio of 2.69. Microbot Medical has a one year low of $1.38 and a one year high of $19.40. The firm has a market capitalization of $27.57 million, a price-to-earnings ratio of -2.60 and a beta of 5.04.

Microbot Medical (NASDAQ:MBOT) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.09. Equities research analysts anticipate that Microbot Medical will post -1.33 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley lifted its holdings in shares of Microbot Medical by 77.0% during the 2nd quarter. Morgan Stanley now owns 6,316 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 2,748 shares during the last quarter. Geode Capital Management LLC bought a new stake in shares of Microbot Medical during the 4th quarter worth $38,000. JPMorgan Chase & Co. bought a new stake in shares of Microbot Medical during the 2nd quarter worth $45,000. BlackRock Inc. lifted its holdings in shares of Microbot Medical by 5.7% during the 2nd quarter. BlackRock Inc. now owns 183,520 shares of the biotechnology company’s stock worth $945,000 after acquiring an additional 9,906 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Microbot Medical by 5.5% during the 2nd quarter. Renaissance Technologies LLC now owns 206,887 shares of the biotechnology company’s stock worth $1,065,000 after acquiring an additional 10,838 shares during the last quarter. 14.79% of the stock is owned by institutional investors.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.

Further Reading: How to trade on quiet period expirations

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.